StockWatch
·
Pharmaceuticals
Quarterly Result7 Nov 2026, 12:00 pm

Divi's Labs consolidated PAT surges 64% YoY to ₹1,127 Cr, margins hit record 42.6%

AI Summary

Divi's Laboratories posted consolidated total income of ₹3,770 Cr for Q2 FY27, with revenue from operations up 35.4% YoY (and 19.4% QoQ) to ₹3,676 Cr, and PAT up 63.6% YoY (24.9% QoQ) to ₹1,127 Cr. The print clears the pre-result preview's on-plan range on every count: revenue (₹3,100–3,200 Cr expected vs ₹3,676 Cr actual), EBITDA margin (38–41% expected vs ~42.6% actual) and PAT (₹800–900 Cr expected vs ₹1,127 Cr actual) — resolving the Street's Q1-era debate (level-change vs peak) in favour of a level change, at least for this quarter. It also clears management's own August guidance of "double-digit FY27 revenue growth" and EBITDA "similar to FY26" by a wide margin — FY26's full-year EBITDA margin ran near 32–33%, roughly 10 percentage points below this quarter's print. The margin expansion is broad-based rather than a single line item: gross margin (revenue less material cost and inventory movement) works out to roughly 68%, well above the ~60% management flagged for the year, helped by a ₹631 Cr build in finished-goods/WIP inventory that reduced the reported cost-of-materials line. EBITDA margin (OPM) expanded to ~42.6% from 32.7% a year ago and 40.8% last quarter, while net margin improved to 29.9% from 24.1% YoY and 28.7% QoQ — both metrics trending up sequentially for a second straight quarter, not just a one-off pop. H1 FY27 consolidated PAT stands at ₹2,029 Cr on revenue of ₹6,756 Cr, up 64.5% and 31.8% respectively over H1 FY26, confirming this isn't a single-quarter anomaly after Q1's similarly strong ₹902 Cr PAT (+66% YoY, per the prior release). Standalone tracks consolidated closely (PAT ₹1,140 Cr, +63.8% YoY), so there's no meaningful standalone-vs-consolidated story to flag. The company's own press release is a factual recap of the total income/PBT/PAT figures with no incremental qualitative commentary on drivers or outlook beyond what was already said on the August concall; the board otherwise used the November 7 meeting only to approve the results and press release, with no other business items disclosed in this filing. What this sets up: management's prior capex update (three projects ~70% capitalised, ₹1,400 Cr of ₹2,000 Cr) is broadly consistent with CWIP declining to ₹1,638 Cr from ₹2,113 Cr at FY26-end as PP&E rose to ₹7,452 Cr — capitalisation is progressing, though this filing doesn't break out project-level capex to confirm the exact 70% figure.

Key Highlights

  • Consolidated PAT ₹1,127 Cr, +63.6% YoY and +24.9% QoQ — a record quarter following Q1's ₹902 Cr
  • Revenue from operations ₹3,676 Cr, +35.4% YoY / +19.4% QoQ, well ahead of the 'double-digit' FY27 guidance
  • EBITDA margin (OPM) expanded to ~42.6% from 32.7% YoY and 40.8% QoQ — above the pre-result Street range of 38–41% and FY26's full-year ~32–33%
  • NPM improved to 29.9% from 24.1% a year ago and 28.7% last quarter
  • H1 FY27 consolidated PAT ₹2,029 Cr (+64.5% YoY) on revenue ₹6,756 Cr (+31.8% YoY) — confirms the trend isn't a single-quarter spike
  • Beat the pre-result preview's on-plan expectations across revenue, EBITDA margin and PAT
  • No exceptional items this quarter (unlike FY26's full-year ₹74 Cr labour-code impact), so growth is on a clean base